Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Long-Term Deferred Tax (2019 - 2021)

Legend Biotech filings provide 3 years of Long-Term Deferred Tax readings, the most recent being $22.8 million for Q4 2021.

  • On a quarterly basis, Long-Term Deferred Tax fell 25.98% to $22.8 million in Q4 2021 year-over-year; TTM through Dec 2021 was $22.8 million, a 25.98% decrease, with the full-year FY2021 number at $22.8 million, down 25.98% from a year prior.
  • Long-Term Deferred Tax hit $22.8 million in Q4 2021 for Legend Biotech, down from $30.8 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $30.8 million in Q4 2020 to a low of $5.7 million in Q4 2019.
  • Median Long-Term Deferred Tax over the past 3 years was $22.8 million (2021), compared with a mean of $19.8 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 438.86% in 2020 and later decreased 25.98% in 2021.
  • Legend Biotech's Long-Term Deferred Tax stood at $5.7 million in 2019, then soared by 438.86% to $30.8 million in 2020, then decreased by 25.98% to $22.8 million in 2021.
  • The last three reported values for Long-Term Deferred Tax were $22.8 million (Q4 2021), $30.8 million (Q4 2020), and $5.7 million (Q4 2019) per Business Quant data.